Business Description
United Therapeutics Corp
NAICS : 325412
SIC : 2834
ISIN : US91307C1027
Share Class Description:
STU:UTH: Ordinary SharesDescription
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.32 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.26 | |||||
| Interest Coverage | 26.84 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 12.67 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 11.1 | |||||
| 3-Year FCF Growth Rate | -1.2 | |||||
| 3-Year Book Growth Rate | 18.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.01 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.62 | |||||
| 9-Day RSI | 57.37 | |||||
| 14-Day RSI | 56.58 | |||||
| 6-1 Month Momentum % | 29.91 | |||||
| 12-1 Month Momentum % | 52.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.58 | |||||
| Quick Ratio | 4.41 | |||||
| Cash Ratio | 3.81 | |||||
| Days Inventory | 148.37 | |||||
| Days Sales Outstanding | 39.13 | |||||
| Days Payable | 6.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 7.63 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.94 | |||||
| Operating Margin % | 48.78 | |||||
| Net Margin % | 40.31 | |||||
| FCF Margin % | 32.54 | |||||
| ROE % | 19.26 | |||||
| ROA % | 16.09 | |||||
| ROIC % | 27.13 | |||||
| ROC (Joel Greenblatt) % | 120.95 | |||||
| ROCE % | 24.46 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.27 | |||||
| Forward PE Ratio | 13.9 | |||||
| PE Ratio without NRI | 15.54 | |||||
| Shiller PE Ratio | 25.31 | |||||
| Price-to-Owner-Earnings | 19.64 | |||||
| PS Ratio | 6.56 | |||||
| PB Ratio | 2.71 | |||||
| Price-to-Tangible-Book | 2.76 | |||||
| Price-to-Free-Cash-Flow | 20.14 | |||||
| Price-to-Operating-Cash-Flow | 15.92 | |||||
| EV-to-EBIT | 9.15 | |||||
| EV-to-Forward-EBIT | 9.14 | |||||
| EV-to-EBITDA | 8.76 | |||||
| EV-to-Forward-EBITDA | 8.62 | |||||
| EV-to-Revenue | 4.94 | |||||
| EV-to-Forward-Revenue | 4.29 | |||||
| EV-to-FCF | 15.16 | |||||
| Price-to-Projected-FCF | 1.65 | |||||
| Price-to-Median-PS-Value | 1.37 | |||||
| Price-to-Graham-Number | 1.38 | |||||
| Price-to-Net-Current-Asset-Value | 5.55 | |||||
| Price-to-Net-Cash | 7.17 | |||||
| Earnings Yield (Greenblatt) % | 10.93 | |||||
| FCF Yield % | 5.43 | |||||
| Forward Rate of Return (Yacktman) % | 22.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
United Therapeutics Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,526.065 | ||
| EPS (TTM) (€) | 20.866 | ||
| Beta | 0.39 | ||
| Volatility % | 24.44 | ||
| 14-Day RSI | 56.58 | ||
| 14-Day ATR (€) | 7.794968 | ||
| 20-Day SMA (€) | 359.185 | ||
| 12-1 Month Momentum % | 52.9 | ||
| 52-Week Range (€) | 191.9 - 388.6 | ||
| Shares Outstanding (Mil) | 44.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
United Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
United Therapeutics Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
United Therapeutics Corp Frequently Asked Questions
What is United Therapeutics Corp(STU:UTH)'s stock price today?
The current price of STU:UTH is €361.10. The 52 week high of STU:UTH is €388.60 and 52 week low is €191.90.
When is next earnings date of United Therapeutics Corp(STU:UTH)?
The next earnings date of United Therapeutics Corp(STU:UTH) is 2025-02-21 Est..
Does United Therapeutics Corp(STU:UTH) pay dividends? If so, how much?
United Therapeutics Corp(STU:UTH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers